MNPRMonopar Therapeutics Inc.
$83.72-15% 1Y
$83.72
$50.1252 weeks$124.25
Price
-15%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality strong, a flag to check, the market undecided.
P/En/a
Market value$560.8M
1 year-15%
5 years+244%
Charts
As reported to the SEC, without any scoring.
Monopar Therapeutics Inc. (MNPR) reported revenue of $0 in Q2 2026 (quarter ended Jun 30, 2026). That came with net loss of $5.3M. For the full year FY2025, revenue was $0 and net income −$14M. The next results filing is expected around Nov 12, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 22, 2026Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease.Regulation FD disclosure · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.